Skip to main content
Venus Remedies Ltd. logo

Venus Remedies Ltd. — Investor Relations & Filings

Ticker · VENUSREM ISIN · INE411B01019 LEI · 335800PBHMB6GQMFN127 BSE.NS Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country IN India
Listing BSE.NS VENUSREM

About Venus Remedies Ltd.

https://venusremedies.com/

Venus Remedies Ltd. is a research-driven organization specializing in the development and manufacturing of innovative pharmaceutical formulations. The company focuses on critical therapeutic segments, including antimicrobial resistance, oncology, neurology, orthopedics, and pain management. It operates advanced manufacturing facilities and maintains a dedicated research and development wing, the Venus Medicine Research Centre, which prioritizes the creation of novel drug delivery systems and solutions for multi-drug resistant infections. Its product portfolio features a diverse range of injectables and specialized treatments, such as Elores, aimed at addressing complex clinical needs. The company serves a global market, providing healthcare solutions through a commitment to scientific excellence and international regulatory standards.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 75% confidence The document is an intimation under Regulation 30 of the SEBI LODR regulations, submitting a press release to stock exchanges about a marketing authorization approval. It is a regulatory disclosure announcement with no financial statements or substantive report content. This falls under general regulatory/compliance filings rather than a financial report or other specific categories. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-22 English
As per the pdf enclosed
Regulatory Filings Classification · 87% confidence The document is a press release filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notifying the exchange of a corporate development (Saudi FDA approval). It contains no financial statements or data, and is a routine regulatory/intelligence announcement. This fits the “Regulatory Filings” category as a general announcement (RNS), not a financial report or ESG disclosure.
2026-05-22 English
Updates
Regulatory Filings Classification · 85% confidence The document is a notification to the National Stock Exchange and BSE under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) regarding social media communications for KYC updation. It is a compliance/regulatory announcement rather than a financial report, dividend notice, or management discussion. This fits the fallback category for general regulatory filings.
2026-05-21 English
Social media Post on KYC updation.
Regulatory Filings Classification · 90% confidence The document is a stock exchange filing under SEBI Listing Regulation 30, disclosing social media links for shareholder KYC awareness. It is not a financial report, earnings release, or management change, nor is it announcing a report publication. It is a general regulatory compliance announcement, fitting the fallback category “Regulatory Filings” (RNS).
2026-05-21 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2026-05-19 English
Board meeting is scheduled for 26th May 2026.
Regulatory Filings Classification · 91% confidence The document is a notice under SEBI LODR Regulation 29 informing stock exchanges of a forthcoming Board meeting to approve financial results, recommend dividends, and discuss the AGM. It does not itself contain financial statements or final results, nor is it a change in management or a meeting transcript. It is a regulatory announcement of compliance rather than the report itself, so it falls under the general Regulatory Filings category (RNS).
2026-05-15 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.